Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties

Abstract The CB1 inverse agonist/antagonist SR141716A recently has been introduced for the management of obesity (rimonabant; Acomplia) and appears to have beneficial effects. However, its utility may be hampered in some individuals by adverse effects including nausea or emesis or by mood depression...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Physiology & behavior 2008-03, Vol.93 (4), p.666-670
Hauptverfasser:	Bergman, Jack, Delatte, Marcus S, Paronis, Carol A, Vemuri, Kiran, Thakur, Ganesh A, Makriyannis, Alex
Format:	Artikel
Sprache:	eng
Schlagworte:	AM4054 AM4113 Animals Behavior Behavior, Animal - drug effects Behavioral psychophysiology Biological and medical sciences Conditioning, Operant - drug effects Drug Interactions Fundamental and applied biological sciences. Psychology Hypothermia Inverse agonism Neutral antagonism Piperidines - pharmacology Psychiatry Psychology. Psychoanalysis. Psychiatry Psychology. Psychophysiology Pyrazoles - pharmacology Receptor, Cannabinoid, CB1 - agonists Receptor, Cannabinoid, CB1 - antagonists & inhibitors Receptor, Cannabinoid, CB1 - physiology Rimonabant SR141716A
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!